Company Filing History:
Years Active: 2014-2025
Title: Stéphane Ciblat: Innovator in NLRP3 Inhibition
Introduction
Stéphane Ciblat is a notable inventor based in Montreal, Canada. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that inhibit the NLRP3 protein. With a total of 5 patents to his name, Ciblat's work is paving the way for new treatments for various diseases.
Latest Patents
Ciblat's latest patents include innovative pyridazine compounds designed for inhibiting NLRP3. These compounds are useful in treating diseases and disorders associated with this protein. His disclosures detail the chemical structures and formulations of these inhibitors, including pyrido-[3,4-d]pyridazine amine derivatives, which are also aimed at providing therapeutic benefits.
Career Highlights
Throughout his career, Ciblat has worked with several prominent companies, including Ventus Therapeutics and BHI Limited Partnership. His expertise in drug development and molecular design has been instrumental in advancing research in the pharmaceutical industry.
Collaborations
Ciblat has collaborated with notable professionals in his field, including Stéphane Dorich and Xianqi Kong. These partnerships have enhanced his research and contributed to the successful development of his patented compounds.
Conclusion
Stéphane Ciblat is a distinguished inventor whose work in NLRP3 inhibition is making a significant impact in the medical field. His innovative patents and collaborations reflect his commitment to advancing healthcare solutions.